Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:57 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 629 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: quinolone Clear all

Conditions: Pulmonary Sarcoidosis, Lung Function
Interventions: levaquin; ethambutol; rifampin and azithromycin.; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Late Life Treatment Resistant Depression, Depression - Major Depressive Disorder, Treatment Resistant Depression
Interventions: Aripiprazole Augmentation, Bupropion Augmentation; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 60 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: St Louis, Missouri • Pittsburgh, Pennsylvania

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: aripiprazole, Sugar pill; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 6 Years to 17 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Urinary Tract Infections, Catheter-Related Infections
Interventions: methenamine hippurate, Ciprofloxacin; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older · Female only
Enrollment: 201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 4
States / cities: Philadelphia, Pennsylvania

Conditions: Tuberculosis, Pulmonary
Interventions: moxifloxacin (with isoniazid, rifampin, pyrazinamide); Drug
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 18 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 18
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 13 more

Conditions: Healthy
Interventions: MK-8527, Moxifloxacin, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Marlton, New Jersey

Conditions: Cardiovascular Diseases, Dysphagia
Interventions: Fiberoptic Endoscopic Evaluation of Swallowing, Simultaneous FEES and Videofluoroscopy instrumental swallowing exam, Videofluoroscopy instrumental swallowing exam (VFSS), Voluntary Cough Peak Expiratory Flow (PEF) Testing, Reflex Cough Screen, Lingual Pressure Testing, Speech Testing; Diagnostic Test · Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 90 Years
Enrollment: 347 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 2
States / cities: Gainesville, Florida • Columbus, Ohio

Conditions: Prolonged QTc Interval
Interventions: Estetrol 20 mg, Estetrol 100 mg, Placebo, Moxifloxacin 400 mg; Drug
Lead sponsor: Estetra; Industry
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Asperger's Disorder, Pervasive Developmental Disorder
Interventions: aripiprazole; Drug
Lead sponsor: Indiana University; Other
Eligibility: 4 Years to 17 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Healthy
Interventions: ODV Placebo (Matching 25 mg ODV), ODV Placebo (Matching 200 mg ODV), ODV Placebo (Matching 125 mg ODV), ODV Placebo (Matching 100 mg ODV), SMV Placebo (Matching 150 mg SMV), AL-335 Placebo (matching 1200 mg AL-335), Moxifloxacin Placebo (matching 400 mg moxifloxacin), ODV 25 mg, ODV 200 mg, ODV 125 mg, ODV 100 mg, SMV 150 mg, AL-335 1200 mg; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Schizophenia Disorder
Interventions: aripiprazole, risperidone, clozapine; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years to 35 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 4
States / cities: Birmingham, Alabama • La Jolla, California • Belmont, Massachusetts + 1 more

Conditions: Schizophenia Disorder, Schizoaffective Disorder
Interventions: aripiprazole; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 52 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Pneumonia
Interventions: azithromycin sustained release, placebo, levofloxacin; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 468 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 35
States / cities: Mesa, Arizona • Phoenix, Arizona • San Luis Obispo, California + 28 more

Conditions: Healthy
Interventions: Setmelanotide, Moxifloxacin, Oral Placebo, SC Placebo; Drug
Lead sponsor: Rhythm Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 77 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Glendale, California

Conditions: Malaria, Vivax
Interventions: Tafenoquine 300mg, Tafenoquine 600mg, Tafenoquine 1200mg, moxifloxacin, Placebo for Tafenoquine, Placebo for moxifloxaxin; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 260 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Culver City, California • Baltimore, Maryland

Conditions: Tourette's Syndrome, Tic Disorders
Interventions: Aripiprazole; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 7 Years to 18 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy
Interventions: ABBV-CLS-7262, Placebo, Moxifloxacin 400mg; Drug
Lead sponsor: Calico Life Sciences LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Grayslake, Illinois

Conditions: Schizophrenia
Interventions: Brexpiprazole (OPC-34712), Aripiprazole, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 13 Years to 17 Years
Enrollment: 316 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Schizophrenia, Bipolar Disorder, Depression, Psychotic Disorders
Interventions: aripiprazole; fluoxetine; bupropion; sertraline; lamotrigine, Psychoeducational multifamily group treatment, Supported employment and education; Drug · Behavioral
Lead sponsor: MaineHealth; Other
Eligibility: 12 Years to 25 Years
Enrollment: 292 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 6
States / cities: Sacramento, California • Portland, Maine • Ann Arbor, Michigan + 3 more

Conditions: Non-Hodgkin's Lymphoma, Cancer
Interventions: Vincristine, VP-16, Rituximab, Dexamethasone, Levofloxacin; Drug
Lead sponsor: New Mexico Cancer Research Alliance; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2014
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Pharmacokinetics
Interventions: PrimeC 748 mg, Ciprofloxacin 750 MG, Celecoxib 200mg; Drug
Lead sponsor: NeuroSense Therapeutics Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Negative Symptoms of Schizophrenia
Interventions: Roluperidone, risperidone, aripiprazole, olanzapine, Placebo; Drug
Lead sponsor: Minerva Neurosciences; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 13
States / cities: Bellflower, California • Culver City, California • Garden Grove, California + 10 more

Conditions: Musculoskeletal Diseases
Interventions: No intervention; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 6 Months to 16 Years
Enrollment: 2,233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2010
U.S. locations: 47
States / cities: Hoover, Alabama • Mobile, Alabama • Phoenix, Arizona + 44 more

Conditions: Healthy
Interventions: HYD, Moxifloxacin, Placebo for HYD, Placebo for moxifloxacin; Drug
Lead sponsor: Purdue Pharma LP; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 208 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Austin, Texas

Search by objective public record fields.

Investigation of the Efficacy of Antibiotics on Pulmonary Sarcoidosis

The BAARD Study : Evaluating a Computerized Approach to Treatment Selection in Older Adults With Treatment Resistant Depression.

Treatment of Children With ADHD Who do Not Fully Respond to Stimulants

Short-course Methenamine Hippurate for Prevention of Post-operative UTI

TBTC Study 27: Moxifloxacin vs Ethambutol for TB Treatment

A Clinical Study of MK-8527 in Healthy Adult Participants (MK-8527-014)

Clinical Markers of Dysphagia in Cardiac Surgical Patients

Effect of Estetrol Monohydrate (E4) on QTc Interval

A Study of Aripiprazole in Children and Adolescents With Aspergers and Pervasive Developmental Disorder.

A Study to Evaluate the Cardiac Safety of a Single Dose of AL-335 Administered on a Background of Simeprevir and Odalasvir and of Repeated Doses of Odalasvir Administered Alone in Healthy Participants

Biomarkers to Enhance Early Schizophrenia Treatment

Study Comparing Patients Taking Olanzapine and Patients Taking Aripiprazole on Learning of Vocational Skills

A Multicenter, Randomized, Double-Blind, Double-Dummy Trial of Azithromycin SR Compared With Levofloxacin for the Treatment of Mild to Moderate Pneumonia in Adult Patients

Study of Setmelanotide Effects on QTc (Corrected QT) Interval in Healthy Participants

Tafenoquine Thorough QTc Study in Healthy Subjects

Open Label Trial of Aripiprazole in Children and Adolescents With Tourette's Disorder

A Thorough QT Study of ABBV-CLS-7262 in Healthy Subjects

Trial to Evaluate the Short-term Safety & Efficacy of Brexpiprazole Monotherapy in the Treatment of Adolescents With Schizophrenia

Early Detection and Intervention for the Prevention of Psychosis

Study: Treatment of Relapsed Lymphoid Malignancies With an Anti-Angiogenic Approach

A Multiple-Dose PK Study to Evaluate the Comparative Bioavailability of PrimeC Tablets to Ciprofloxacin Tablets Co-administered With Celecoxib Capsules, in Healthy Adult Subject

Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications

A Study of Incidence of Musculoskeletal Disorders in Children Who Have Received Levofloxacin or a Standard Non-Fluoroquinolone Therapy for Acute Bacterial Infection

The Effect of Hydrocodone Bitartrate (HYD) Extended-Release Tablets on QT /QTc Intervals in Healthy Adult Subjects